NCT00787332

A Comparative Sudy Comparing Argatroban® IV vs Desirudin SC for Suspected HIT With or Without Thrombosis Syndrome

A Comparative Clinical and Pharmacoeconomic Study Comparing Argatroban® IV vs Desirudin SC for Patients With Suspected Heparin-Induced Thrombocytopenia (HIT)With or Without Thrombosis Syndrome (HIT/TS)

• Status: Terminated
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: Canyon Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Compare Clinical Success and Costs in two Arms

Detailed description

Demonstrate clinical and economic utility between the study Arms.

Conditions

• Suspected Heparin-Induced Thrombocytopenia

Interventions

Type	Name	Description
DRUG	Desirudin or Argatroban®	Desirudin 15mg SC Argatroban® IV dosing per Package Insert

Timeline

• Start date: 2008-09-01
• Primary completion: 2009-12-01
• Completion: 2009-12-01
• First posted: 2008-11-07
• Last updated: 2013-01-10
• Results posted: 2012-12-31

Locations

24 sites across 1 country: United States